Trailing-twelve-month (TTM) revenue is $5.69 Billion with a year-over-year growth of +5.95%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $1,435,016,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-30 |
| Q4 FY2025Period ended 2025-12-31 | $1,465,446,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-24 |
| Q1 FY2026Period ended 2026-03-31 | $1,350,654,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-30 |
| Q2 FY2026Period ended 2026-06-30 | $1,442,400,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-29 |
| TTM revenue | $5,693,516,000 |
Current P/S: $4,650,832,022 market capitalization ÷ $5,693,516,000 TTM revenue = 0.82x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T19:20:25.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $1.44B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T19:23:14.892Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20122012-12-31 · USD | FY20132013-12-31 · USD | FY20142014-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|
| Home Health Services | $69M | $72M | N/A | N/A |
| Infusion Services | N/A | $697M | $923M | N/A |
| PBM Services | $112M | $73M |
$5.69B
$5.69 Billion
+5.95%
vs. $5.37B a year ago (TTM)
+12.17%
5 Year compound annual growth rate
1 Year
+5.95%
3 Year
+11.27%
5 Year
+12.17%
10 Year
+19.46%
15 Year
+11.23%
20 Year
+8.20%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $5.65B | +$651.32M | +13.03% |
| 2024 | $5.00B | +$695.88M | +16.17% |
| 2023 | $4.30B | +$357.59M | +9.06% |
| 2022 | $3.94B | +$506.10M | +14.72% |
| 2021 | $3.44B | +$406.03M | +13.39% |
| 2020 |
TTM Growth
+5.95%
3-Year CAGR
+11.27%
5-Year CAGR
+12.17%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T19:23:14.892Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| N/A |
| Reportable Segment | N/A | N/A | N/A | $5.6B |
|---|
| $3.03B |
| +$722.19M |
| +31.26% |
| 2019 | $2.31B | +$370.63M | +19.11% |
| 2018 | $1.94B | +$1.12B | +137.37% |
| 2017 | $817.19M | ($118.40M) | (12.66%) |
| 2016 | $935.59M | ($46.63M) | (4.75%) |
